Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
NCT02129699 · ETOP IBCSG Partners Foundation · PHASE3 · terminated · last registry update 2026-09-08 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a benefit for denosumab could be shown, these results would be of very limited clinical impact by the time they would be available” | Open Targets' class: insufficient enrollment | Registry record, ETOP IBCSG Partners Foundation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision